These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34089793)

  • 41. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
    Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
    Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Computational design of ultrashort peptide inhibitors of the receptor-binding domain of the SARS-CoV-2 S protein.
    Pei P; Qin H; Chen J; Wang F; He C; He S; Hong B; Liu K; Qiao R; Fan H; Tong Y; Chen L; Luo SZ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34180984
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Site Density Functional Theory and Structural Bioinformatics Analysis of the SARS-CoV Spike Protein and hACE2 Complex.
    Kumawat N; Tucs A; Bera S; Chuev GN; Valiev M; Fedotova MV; Kruchinin SE; Tsuda K; Sljoka A; Chakraborty A
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
    Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
    Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
    David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
    Molecules; 2021 May; 26(11):. PubMed ID: 34072087
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cell entry mechanisms of SARS-CoV-2.
    Shang J; Wan Y; Luo C; Ye G; Geng Q; Auerbach A; Li F
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11727-11734. PubMed ID: 32376634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of Coronavirus Entry
    Outlaw VK; Bovier FT; Mears MC; Cajimat MN; Zhu Y; Lin MJ; Addetia A; Lieberman NAP; Peddu V; Xie X; Shi PY; Greninger AL; Gellman SH; Bente DA; Moscona A; Porotto M
    mBio; 2020 Oct; 11(5):. PubMed ID: 33082259
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antigenic Cross-Reactivity Between SARS-CoV-2 S1-RBD and Its Receptor ACE2.
    Lai YC; Cheng YW; Chao CH; Chang YY; Chen CD; Tsai WJ; Wang S; Lin YS; Chang CP; Chuang WJ; Chen LY; Wang YR; Chang SY; Huang W; Wang JR; Tseng CK; Lin CK; Chuang YC; Yeh TM
    Front Immunol; 2022; 13():868724. PubMed ID: 35603169
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2.
    Wang X; Yang C; Sun Y; Sui X; Zhu T; Wang Q; Wang S; Yang J; Yang W; Liu F; Zhang M; Wang Y; Luo Y
    Environ Int; 2021 Feb; 147():106361. PubMed ID: 33401173
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential antiviral peptides targeting the SARS-CoV-2 spike protein.
    Khater I; Nassar A
    BMC Pharmacol Toxicol; 2022 Dec; 23(1):91. PubMed ID: 36461109
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of the Role of N-Linked Glycosylation in Cell Surface Expression, Function, and Binding Properties of SARS-CoV-2 Receptor ACE2.
    Rowland R; Brandariz-Nuñez A
    Microbiol Spectr; 2021 Oct; 9(2):e0119921. PubMed ID: 34494876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Natural Stilbenoid (-)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants.
    Tietjen I; Cassel J; Register ET; Zhou XY; Messick TE; Keeney F; Lu LD; Beattie KD; Rali T; Tebas P; Ertl HCJ; Salvino JM; Davis RA; Montaner LJ
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0077221. PubMed ID: 34543092
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins.
    Zang Y; Li X; Zhao Y; Wang H; Hao D; Zhang L; Yang Z; Yuan X; Zhang S
    Phys Chem Chem Phys; 2021 Jun; 23(24):13752-13759. PubMed ID: 34132301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Millisecond dynamic of SARS-CoV-2 spike and its interaction with ACE2 receptor and small extracellular vesicles.
    Lim K; Nishide G; Yoshida T; Watanabe-Nakayama T; Kobayashi A; Hazawa M; Hanayama R; Ando T; Wong RW
    J Extracell Vesicles; 2021 Dec; 10(14):e12170. PubMed ID: 34874124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tinocordiside from
    Balkrishna A; Pokhrel S; Varshney A
    Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.